This study investigated the safety and immunogenicity of the inactivated CoronaVac vaccine in children and adolescents (3-17 years old) in Chile. The vaccine proved safe, inducing both neutralizing antibodies and CD4+ T cell responses against SARS-CoV-2, including its Delta and Omicron variants, though antibody titers were lower for these variants.
What Problem Does This Paper Address?
While numerous vaccines against SARS-CoV-2 have been developed and tested in adults, there's a significant gap in understanding their immune responses in pediatric populations. Specifically, data on the safety and effectiveness of inactivated vaccines like CoronaVac in children and adolescents has been limited. This paper aims to fill that gap by evaluating the immune response, including antibody production and T cell activation, to CoronaVac in this age group, particularly in the context of emerging SARS-CoV-2 variants.
Methods
The study employed a phase 3 clinical trial design in Chile, administering two doses of CoronaVac four weeks apart to healthy children and adolescents aged 3 to 17 years. Safety was assessed by monitoring local and systemic adverse events. Immunogenicity was evaluated by analyzing whole-blood samples from a subgroup of participants. Key techniques included:
Humoral immunity assessment:
Chemiluminescence immunoassay (ADVIA Centaur XP SARS-CoV-2 IgG): To quantify total IgG antibodies against the S1 receptor-binding domain (RBD) of SARS-CoV-2.
Surrogate viral neutralization test (sVNT): To measure neutralizing antibodies by assessing the blockage of S1 RBD interaction with hACE2.
Conventional virus neutralization test (cVNT): To determine neutralizing antibody titers against the ancestral SARS-CoV-2 virus.
Pseudotyped virus neutralization assay (pVNT): To evaluate neutralizing antibody responses against SARS-CoV-2 variants (Delta and Omicron) compared to the ancestral strain.
Cellular immunity assessment:
Flow cytometry: To quantify activated CD4+ T cells (expressing AIM markers OX40 and CD137) and memory AIM+ CD4+ T cells after stimulation with SARS-CoV-2 peptide megapools (MPs).
Luminex technology: To measure cytokine secretion (IL-2, IFN-γ, IL-4) from stimulated peripheral blood mononuclear cells (PBMCs).
ELISPOT: Used to evaluate IFN-γ and IL-4 production, though limitations were noted.
Datasets
The study utilized data from 963 participants in Chile aged 3 to 17 years who received two doses of CoronaVac. A subgroup of 148 participants was selected for immunogenicity analyses. Blood samples were collected at baseline (pre-vaccination) and four weeks after the second dose. The study also referenced data from previous trials and studies involving other SARS-CoV-2 vaccines and variants.
Key Insights and Ideas
Pediatric Immunogenicity is Comparable: The study demonstrates that CoronaVac elicits robust humoral and cellular immune responses in children and adolescents, comparable to what has been observed in adult populations. This is crucial for understanding vaccine efficacy in younger age groups.
Cellular Immunity Bridges Variant Gaps: While neutralizing antibody titers against the Delta and Omicron variants were lower than against the ancestral strain, the CD4+ T cell response remained strong and comparable, even showing a significant increase against Omicron. This suggests that cellular immunity might offer a more stable defense against emerging variants.
Broad Viral Protein Recognition: The cellular immune response was not limited to the Spike protein but also extended to the M and N proteins of SARS-CoV-2, indicating a broader recognition of viral components by T cells.
Th1 Profile Induction: The observed cytokine profiles (increased IL-2 and IFN-γ, but not IL-4) suggest that CoronaVac stimulates a Th1-biased immune response, which is generally associated with effective viral clearance.
Key Results
Safety: CoronaVac was found to be safe in children and adolescents, with the most common adverse event being mild to moderate pain at the injection site. No serious adverse events (SAEs) related to the vaccine were reported.
Antibody Response: Two doses of CoronaVac significantly increased total IgG anti-S1 RBD antibodies and neutralizing antibody titers four weeks after the second dose. Seropositivity reached high levels (e.g., 100% for sVNT).
Variant Neutralization: Neutralizing antibody titers against Delta and Omicron variants were reduced (1.9-fold for Delta, 15.8-fold for Omicron) compared to the D614G strain. However, the 3-11 year old group showed a significantly higher neutralizing antibody response against Omicron.
T Cell Response: A significant increase in activated CD4+ T cells (AIM+ CD4+ T cells) was observed in both age groups after vaccination, with broader recognition of viral proteins in the 12-17 year old group. Memory CD4+ T cell responses were also induced.
Variant T Cell Recognition: CD4+ T cell responses against Delta and Omicron variants were comparable to the ancestral strain, with a significant increase against Omicron.
Limitations and Future Work
Short-Term Safety Follow-up: The authors acknowledge that the safety follow-up period was relatively short. For rare SAEs like myocarditis, the sample size and observation time might be insufficient for detection.
Limited Blood Volume: The small blood volume obtained from younger participants limited the scope of some assays, particularly for repeating complex analyses.
Asymptomatic Infections: The study relied on RT-qPCR for symptomatic cases only, meaning asymptomatic infections could not be ruled out and might have influenced results.
Long-Term Immunity: Information on the long-term immune response and durability of protection in the pediatric population is still limited.
Future work should focus on longer-term follow-up to assess the duration of immunity and explore the potential benefits of booster doses, possibly using heterologous or homologous vaccination schedules, to enhance protection against emerging variants. Further research is also needed to understand the specific mechanisms behind the increased CD4+ T cell response against the Omicron variant in this pediatric population.
Summary updated
Abstract
Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. Here, we report interim safety and immunogenicity results of a phase 3 clinical trial for CoronaVac in healthy children and adolescents in Chile. Participants 3 to 17 years old received two doses of CoronaVac in a 4-week interval until 31 December 2021. Local and systemic adverse reactions were registered for volunteers who received one or two doses of CoronaVac. Whole-blood samples were collected from a subgroup of 148 participants for humoral and cellular immunity analyses. The main adverse reaction reported after the first and second doses was pain at the injection site. Four weeks after the second dose, an increase in neutralizing antibody titer was observed in subjects relative to their baseline visit. Similar results were found for activation of specific CD4<sup>+</sup> T cells. Neutralizing antibodies were identified against the Delta and Omicron variants. However, these titers were lower than those for the D614G strain. Importantly, comparable CD4<sup>+</sup> T cell responses were detected against these variants of concern. Therefore, CoronaVac is safe and immunogenic in subjects 3 to 17 years old, inducing neutralizing antibody secretion and activating CD4<sup>+</sup> T cells against SARS-CoV-2 and its variants. (This study has been registered at ClinicalTrials.gov under no. NCT04992260.) <b>IMPORTANCE</b> This work evaluated the immune response induced by two doses of CoronaVac separated by 4 weeks in healthy children and adolescents in Chile. To date, few studies have described the effects of CoronaVac in the pediatric population. Therefore, it is essential to generate knowledge regarding the protection of vaccines in this population. Along these lines, we reported the anti-S humoral response and cellular immune response to several SARS-CoV-2 proteins that have been published and recently studied. Here, we show that a vaccination schedule consisting of two doses separated by 4 weeks induces the secretion of neutralizing antibodies against SARS-CoV-2. Furthermore, CoronaVac induces the activation of CD4<sup>+</sup> T cells upon stimulation with peptides from the proteome of SARS-CoV-2. These results indicate that, even though the neutralizing antibody response induced by vaccination decreases against the Delta and Omicron variants, the cellular response against these variants is comparable to the response against the ancestral strain D614G, even being significantly higher against Omicron.
BibTeX
@inproceedings{soto2022inactivated,
author = {Jorge A. Soto and Felipe Melo-González and Cristián Gutiérrez-Vera and Bárbara M. Schultz and Roslye V. Berríos-Rojas and Daniela Rivera-Pérez and Alejandro Piña-Iturbe and Guillermo Hoppe-Elsholz and Luisa F. Duarte and Yaneisi Vázquez and Daniela Moreno‐Tapia and Mariana Ríos and Pablo A Palacios and Richard García-Betancourt and Álvaro Santibáñez and Gaspar A. Pacheco and Constanza Méndez and Catalina A. Andrade and Pedro H. Silva and Benjamín Diethelm‐Varela and Patricio Astudillo and Mario Calvo and Antonio Cárdenas and Marcela González and Macarena Goldsack and Valentina Gutiérrez and Marcela Potı́n and Andrea Schilling and Lorena Tapia and Loreto Twele and Rodolfo Villena and Alba Grifoni and Alessandro Sette and Daniela Weiskopf and Rodrigo Fasce and Jorge Onrubia Fernández and Judith Mora and Eugenio Ramı́rez and Aracelly Gaete-Argel and Mónica L. Acevedo and Fernando Valiente‐Echeverría and Ricardo Soto‐Rifo and Angello Retamal‐Díaz and Nathalia Muñoz-Jofré and Xing Meng and Qianqian Xin and Eduardo Alarcón‐Bustamante and José Vicente González-Aramúndiz and Nicole Le Corre and María Javiera Álvarez-Figueroa and Pablo A. González and Katia Abarca and Cecilia Perret and Leandro J. Carreño and Susan M. Bueno and Alexis M. Kalergis and Patricio Astudillo and Epifanía Hernández Jara and Héctor Morán Fernández and Javiera Arenas Urra and Stephani Ascui Baeza and María Olivia Cabrera and Jose R. Munoz and Gonzalo Alarcón Andrade and Rocío Rodríguez Espósito and Anwar Gutiérrez Silva and Fernanda Pérez Gutiérrez and Alma Muñoz and Marcela Potin Santander and S.Mezquita Lopez and Tania Weil and Macarena Goldsack and Deidyland Arenas and Andrea Araya and Javiera Moore and Lorena Pilicita and Vania Valenzuela and Catalina Campos and Mauricio Soto and Andrea Schilling and Alberto Trautmann and Ana Fritis and Daniela Pavez and Javiera Arancibia and Lilian Rubio and Paula Viviani and Vinka Basic and Cassandra Cárcamo and Mario Calvo Gil and M. Wenzel and Nicole Carey and Roberto Aretxaga Burgos and Loreto Twele and Daniel Beltrán and Silvana Grandón and Carlos Tovar and Marcela González and Daniela Fuentes and Teresa Ramírez and Mariela Corrales},
title = {{Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children}},
booktitle = {mBio},
year = {2022},
doi = {10.1128/mbio.01311-22},
}